Crizotinib (PF-02341066)

Licensed by Pfizer 製品コードS1068

Crizotinib (PF-02341066)化学構造

分子量(MW):450.34

Crizotinib (PF-02341066)は一種の有効なc-MetとALK阻害剤で、細胞試験でIC50値が11 nMと24 nMです。

サイズ 価格(税別) 在庫  
JPY 36520.00 あり
JPY 18260.00 あり
JPY 28220.00 あり
JPY 94620.00 あり

文献中の使用例(71)

カスタマーフィードバック(12)

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

    Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

  • (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

製品安全説明書

c-Met阻害剤の選択性比較

生物活性

製品説明 Crizotinib (PF-02341066)は一種の有効なc-MetとALK阻害剤で、細胞試験でIC50値が11 nMと24 nMです。
ターゲット
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
体外試験

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NXKzbYJLS3m2b4TvfIlkKEG|c3H5 NUHvfmNLPDhiaB?= NUTqUFl4TE2VTx?= M2fKXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2= MYeyNVU4OjV6OR?=
BAF3 MknhR5l1d3SxeHnjJGF{e2G7 Mm\vOFghcA>? M3jJUmROW09? NELr[5pEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGwyOTl4TTDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFIvOiEQvF2= NYnrPYxHOjF3N{K1PFk>
BAF3 NXHqcYp[S3m2b4TvfIlkKEG|c3H5 MUG0PEBp M{PhXGROW09? NHHsO2pEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtid3n0bEBKSzVyIH;mJFAvOjhizszN NFn0NGEzOTV5MkW4PS=>
Kelly NGX4[lREgXSxdH;4bYMhSXO|YYm= M3TzTGROW09? MkLLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4VtdHliY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCC5aYToJGlEPTBib3[gNE41OiEQvF2= MWeyNVU4OjV6OR?=
SH-SY5Y Ml;jR5l1d3SxeHnjJGF{e2G7 MUjEUXNQ M4fofWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC53MzFOwG0> NE\NcGszOTV5MkW4PS=>
SMS-KCN NUDqd5J[S3m2b4TvfIlkKEG|c3H5 M4\WOGROW09? NHSyRplEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUVVNvS1POJINmdGy|IHX4dJJme3OrbnegRWxMKFJzMke1VUBufXSjboSge4l1cCCLQ{WwJI9nKDBwOUGg{txO NEC3cnEzOTV5MkW4PS=>
BAF3 NWfKZlk4S3m2b4TvfIlkKEG|c3H5 MlfPOFghcA>? NUD3XGlsTE2VTx?= NFPqWlhEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= NHvqZ2gzOTV5MkW4PS=>
3T3 Ml3MSpVv[3Srb36gRZN{[Xl? NVvydll6OSCq NH7kPIxFVVOR M1G3emlvcGmkaYTpc44hd2ZiUl;OJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? NFy5W3kzOThzMkSxOC=>
3T3-E M2LPWGZ2dmO2aX;uJGF{e2G7 NInEOGgyKGh? NEHXOZFFVVOR M1ux[2lvcGmkaYTpc44hd2ZiVFnFNkBie3Onc4Pl[EBoem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC52NEig{txO MlzLNlE5OTJ2MUS=
A549 MU\LbY5ie2ViQYPzZZk> MYKxJIg> MUXEUXNQ NWnLc2FrUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDjMW1GXCCtaX7hd4Uh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEig{txO MnH4NlE5OTJ2MUS=
BAF3-BCL MoflSpVv[3Srb36gRZN{[Xl? MYCxJIg> MVrEUXNQ M1P2cGlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? NFTiRWYzOThzMkSxOC=>
HEK293 MXrGeY5kfGmxbjDBd5NigQ>? MYWxJIg> M2PCbmROW09? NHGzRXhKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP M1;r[|IyQDF{NEG0
HEK293 NHfCeHdHfW6ldHnvckBCe3OjeR?= M4rWe|EhcA>? M4LYc2ROW09? M2XHbWlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? MWeyNVgyOjRzNB?=
Jurkat MUXGeY5kfGmxbjDBd5NigQ>? M3XvOFEhcA>? NHvWSGFFVVOR NYnobotGUW6qaXLpeIlwdiCxZjDMR2sh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEKuO|QyKM7:TR?= MYWyNVgyOjRzNB?=
KARPAS299 NUK4UIYyU2mwYYPlJGF{e2G7 NVnxRmFIOSCq NI[xOGRFVVOR MWnJcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> M2TiSFIyQDF{NEG0
PAE M4nXcWZ2dmO2aX;uJGF{e2G7 MYGxJIg> MYHEUXNQ NFjhPGpKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= M2LTUVIyQDF{NEG0
BAF3 MVfGeY5kfGmxbjDBd5NigQ>? MVGyMVMh\A>? NHTFV49FVVOR M33tXmlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIHnud5VtcW5icnXj[ZB1d3JiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjZ2MzFOwG0> MkK1NlM4PDJ{NUK=
KARPAS299 MkLoR5l1d3SxeHnjJGF{e2G7 NHPzV5IzNTNiZB?= M2jUSWROW09? NV61SXIzUUN3ME2wMlA3PDJizszN NUnYT4NTOjN5NEKyOVI>
EBC1 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LjZ|czKGh? NV3z[2NSTE2VTx?= NYjIRZdXUUN3ME2wMlAzOyEQvF2= M3LndFI{QTl|M{K4
HCT116 NInGS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq5S29iPzJiaB?= M3PwV2ROW09? NWnCXnd7UUN3ME2xOE45OiEQvF2= MUGyN|k6OzN{OB?=
MCF7 NWrReWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:3NkBp Mn;nSG1UVw>? M3HWZ2lEPTB;OT61PEDPxE1? NF;IPWQzOzl7M{OyPC=>
MDA-MB-231 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjDSIg4OiCq MVfEUXNQ M2X4TWlEPTB;MUCuPEDPxE1? NY[xN5FQOjN7OUOzNlg>
MKN45 NEHpT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7IO|IhcA>? NWH6XpFGTE2VTx?= NWG1PJp1UUN3ME2wMlAyOyEQvF2= NFHoVJUzOzl7M{OyPC=>
NCI-H441 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHUO|IhcA>? NVLseWhKTE2VTx?= Mn\oTWM2OD1zNz6yOUDPxE1? NWLRWodTOjN7OUOzNlg>
NCI-H661 NFvZOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjYcZk4OiCq NGWzZ3JFVVOR M3vQb2lEPTB;MUGuOFch|ryP M2\WV|I{QTl|M{K4
SK-MEL-28 NVfhblFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp NWnYcHp7TE2VTx?= MmLaTWM2OD1zMD65O{DPxE1? M3fHO|I{QTl|M{K4
SKOV3 MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0b2dlPzJiaB?= MWPEUXNQ MoraTWM2OD1zMj64OUDPxE1? MmnVNlM6QTN|Mki=
SNU5 NXr2cVNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi3NkBp MXnEUXNQ NE\oNYtKSzVyPUCuNFE3KM7:TR?= M4nGXVI{QTl|M{K4
NCI-H2228 NX:0eWlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ey[FczKGh? M3zGUWROW09? NXHORWx2UW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? MV2yOFQ{OjlyOR?=
NCI-H3122 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XvblczKGh? MWrEUXNQ M1XpZWlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> NVftbGlSOjR2M{K5NFk>
NCI-H3122 M1q5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PycFczKGh? M3rtWGROW09? NU[0RZhMUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO MnryNlQ1OzJ7MEm=
NCI-H3122 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P4[|czKGh? NGfST4NFVVOR MlSzTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN MVuyOFQ{OjlyOR?=
NIH-3T3 NVv6TnZJU2mwYYPlJGF{e2G7 NFXJSW8yKGh? NXLoToxtTE2VTx?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? MlOxNlQ1OzJ7MEm=
NIH-3T3 MmeyT4lv[XOnIFHzd4F6 NXq3eY5vOSCq Mor4SG1UVw>? MlHBTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54MEWg{txO NGnqSmUzPDR|MkmwPS=>
NIH-3T3 MlvnT4lv[XOnIFHzd4F6 M2LNSVEhcA>? NVHpR41rTE2VTx?= MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIGOxNlA3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZ{NjFOwG0> NWnhbGQxOjR2M{K5NFk>
NIH-3T3 NH7aRnpMcW6jc3WgRZN{[Xl? NU\jV5F{OSCq M4LOSmROW09? M3;PPWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwOESzJO69VQ>? MmP1NlQ1OzJ7MEm=
NIH-3T3 M2Pvb2tqdmG|ZTDBd5NigQ>? Mlf3NUBp MljGSG1UVw>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> MV[yOFQ{OjlyOR?=
BAF3 MXLGeY5kfGmxbjDBd5NigQ>? NWn2Rm1kPzJiaB?= NWPpW|FRTE2VTx?= NGn4c3JKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO M1\lS|I1PDZ6NkOy
BAF3 M3fvRWN6fG:2b4jpZ{BCe3OjeR?= Mn;2O|IhcA>? MYnEUXNQ M4W0[GlEPTB;MD65PEDPxE1? NVLtSGtTOjR2Nki2N|I>
NIH-3T3 MoH4T4lv[XOnIFHzd4F6 NIXPV5UyKGh? M{\sdWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? NVHLOnVQOjR6MUmxNVY>
NIH-3T3 NYH6c|Q1U2mwYYPlJGF{e2G7 M2fHR|EhcA>? NIPpeJlKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGMyOTV4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkS3PEDPxE1? MVOyOFgyQTFzNh?=
NIH-3T3 NEX6N4tMcW6jc3WgRZN{[Xl? MV[xJIg> NGmwT5ZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? NX\BeIJrOjR6MUmxNVY>
NIH-3T3 Mn3KT4lv[XOnIFHzd4F6 M1XJRVEhcA>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? M4PZd|I1QDF7MUG2
KARPAS299 NUXaXZhsU2mwYYPlJGF{e2G7 NH7rR286OCCvaX6= MWDEUXNQ MnWxTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO NWHCTIxnOjR7MEC3OVA>
MKN 45 MUfLbY5ie2ViQYPzZZk> MXexJIg> NHjUbpVFVVOR M{W1c2lvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? MYeyOFkxODd3MB?=
A549 Mmm3R5l1d3SxeHnjJGF{e2G7 M2LiV|Q5KGh? M17sSWROW09? MniwTWM2OCCxZjC0MlA5PCEQvF2= M2rJTVI1QTByOEOw
NCI-H1975 NFr0PIdEgXSxdH;4bYMhSXO|YYm= MnG3OFghcA>? M{n5OGROW09? M4m4UWlEPTBib3[gO{42PTFizszN Mm\lNlQ6ODB6M{C=
NCI-H1993 NGLJcWlEgXSxdH;4bYMhSXO|YYm= NGHlNms1QCCq MkC5SG1UVw>? Ml;lTWM2OCCxZjCwMlA3OSEQvF2= NETDdI8zPDlyMEizNC=>
NCI-H1993 M3LxPGFxd3Sxc3nzJGF{e2G7 MkP3NUDPxE1? NID4bmMzPCCq MYLEUXNQ NE\K[45ld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz MWeyOFkxODh|MB?=
NIH-3T3 MkDIR5l1d3SxeHnjJGF{e2G7 MUG0PEBp M{HWbmROW09? MkTETWM2OCCxZjCwMlM3PCEQvF2= NV71UmxnOjR7MEC4N|A>
EBC1 M33wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyyZ49WPzJiaB?= NHTvZndFVVOR M37CNGlEPTBib3[gNE4xODZ7IN88US=> MXyyOFkxODh|MR?=
KARPAS299 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C3V|czKGh? Mn\ESG1UVw>? NHHpWXlKSzVyIH;mJFAvOiEQvF2= M325WFI1QTByOEOx
NB1 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Ha[GlEPTB;OUGuPVghdk1? MWfTRW5ITVJ?
NCI-SNU-5 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M321NWlEPTB;MUC1Mlc2KG6P MULTRW5ITVJ?
SR MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[1TWM2OD1zMk[uN|Ehdk1? NInSS5pUSU6JRWK=
SF539 NXHYU|FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTXOlIzUUN3ME2yNFQvOjRibl2= MnrQV2FPT0WU
SU-DHL-1 NFnU[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN|Nj64NkBvVQ>? MWjTRW5ITVJ?
SCC-3 M4Twbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\GPFJKSzVyPUO1Ok44PiCwTR?= Mn;oV2FPT0WU
DEL Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TsdGlEPTB;M{[5Mlkhdk1? NH33NpdUSU6JRWK=
CTV-1 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjjTWM2OD13OU[uOFghdk1? Mk\KV2FPT0WU
EM-2 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfaNYJKSzVyPU[wNU4{PCCwTR?= MmDLV2FPT0WU
MHH-CALL-2 NF[1UnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfRWGxvUUN3ME22PFIvPTdibl2= NX\ZN2p6W0GQR1XS
KM12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX4cFFKSzVyPUewOk46KG6P MlLwV2FPT0WU
KINGS-1 NInIR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETROJFKSzVyPUe0PU44PSCwTR?= MXLTRW5ITVJ?
MEG-01 M{ewZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHkPXdqUUN3ME24OVcvPjZibl2= M{ixXXNCVkeHUh?=
BV-173 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfrSZRKSzVyPUGuNFU6QTdizszN NFLGe|JUSU6JRWK=
LAMA-84 NVyxfGFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmwTWM2OD1zLkO4NlgzKM7:TR?= MUjTRW5ITVJ?
KARPAS-299 NV\XNmV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLZTWM2OD1zLkSwPFYyKM7:TR?= NYHTSWhZW0GQR1XS
K-562 M4e2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q2eGlEPTB;MT63NlI3QSEQvF2= NXjPSoRiW0GQR1XS
SK-LMS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[2[ZdKSzVyPUGuO|Y5PjdizszN MVfTRW5ITVJ?
MOLT-16 M3\oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwOUW1O|Uh|ryP M1HvSHNCVkeHUh?=
CMK NFnNW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zvRmlEPTB;MT65OlE2QSEQvF2= NHuwUWdUSU6JRWK=
ST486 NF\WRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwNEOwO|Mh|ryP NITHXZRUSU6JRWK=
CI-1 NUDSdYFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3HcoRCUUN3ME2yMlQ6PjV7IN88US=> NFSzU5dUSU6JRWK=
KP-N-RT-BM-1 NHHjTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwN{CxNlIh|ryP M3rSfnNCVkeHUh?=
ALL-PO M3TYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\BRlBRUUN3ME2zMlE5OjB5IN88US=> MkHrV2FPT0WU
KS-1 NUDuVZZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNwMkGyNlUh|ryP MWrTRW5ITVJ?
Becker MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTrWYRKSzVyPUSuNlM6OyEQvF2= NHXrc|FUSU6JRWK=
GDM-1 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jPZWlEPTB;ND6yOFYyPyEQvF2= MkG1V2FPT0WU
BC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjK[ZBIUUN3ME20MlQ6Ojd5IN88US=> NV\nXnRkW0GQR1XS
NB14 Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r3R2lEPTB;ND64N|UzPCEQvF2= M4i1PHNCVkeHUh?=
NOS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPkTWM2OD13LkOzPFc1KM7:TR?= MWjTRW5ITVJ?
MZ1-PC M3XEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvhPFNKSzVyPUWuPFIyPTFizszN MkXlV2FPT0WU
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD5UHBKSzVyPU[uNFg1PzNizszN M{n1[nNCVkeHUh?=
EW-16 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwM{e3O|Mh|ryP NHXDSW1USU6JRWK=
NALM-6 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZwNkizPFch|ryP MoC3V2FPT0WU
EB-3 NH7qR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTdwMEeyN|Mh|ryP MoTxV2FPT0WU
697 NH7wepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnqTWM2OD17LkK0N|I6KM7:TR?= Mn;qV2FPT0WU
Ramos-2G6-4C10 NV34cnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nRXmlEPTB;OT61PVg1OiEQvF2= MWXTRW5ITVJ?
KNS-81-FD M{n6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfaO21rUUN3ME25MlY6PjV|IN88US=> MUDTRW5ITVJ?
HUTU-80 M3\uN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTlwN{S2OFIh|ryP MlnkV2FPT0WU
LS-411N MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFyLkC1Olch|ryP NFT1O3dUSU6JRWK=
RPMI-8402 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFyLkGxOkDPxE1? M4HSV3NCVkeHUh?=
KU812 NETHfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn5S|lKSzVyPUGwMlI6QTFizszN MlLvV2FPT0WU
EW-1 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyLkS0NlUh|ryP NUToTm4zW0GQR1XS
HC-1 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzNTWM2OD1zMD60PFQ1KM7:TR?= MWHTRW5ITVJ?
NB69 NX;4W4xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7XVmZEUUN3ME2xNE42ODR|IN88US=> NIHCUGpUSU6JRWK=
MFH-ino NEi1Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fVe2lEPTB;MUCuPFMxOyEQvF2= NF;aZnlUSU6JRWK=
CCRF-CEM NVrGO|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuwfHQ4UUN3ME2xNU42QTdizszN MXzTRW5ITVJ?
SK-N-DZ MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PZ[WlEPTB;MUKuNFQ{PiEQvF2= MmnGV2FPT0WU
NCI-H720 NFzNVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLyTWM2OD1zMj6xO|A2KM7:TR?= NYn2cnNwW0GQR1XS
HCC1187 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHUN|U4UUN3ME2xNk4zODRzIN88US=> MYLTRW5ITVJ?
IST-SL2 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF{LkS4O|Ih|ryP MnHjV2FPT0WU
KE-37 NXTkTFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n2UGlEPTB;MUKuO|k3PiEQvF2= Ml;JV2FPT0WU
HCC1599 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3xfnRDUUN3ME2xNk46ODZ7IN88US=> MULTRW5ITVJ?
A4-Fuk NW\4WG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PW[mlEPTB;MUKuPVU5PiEQvF2= M1fyfHNCVkeHUh?=
NKM-1 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTkTWM2OD1zMz6yPVI2KM7:TR?= M4HUXnNCVkeHUh?=
BE-13 NIC4b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF|Lke5PFkh|ryP MmfKV2FPT0WU
MV-4-11 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLYPYdKSzVyPUG0MlA{OjRizszN MoS4V2FPT0WU
OPM-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPjXlJyUUN3ME2xOE41ODh3IN88US=> M4PuUnNCVkeHUh?=
KARPAS-422 M3rpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLJflNSUUN3ME2xOE42OTJ4IN88US=> MlexV2FPT0WU
RPMI-8226 M1r2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLDTWM2OD1zND64PVE2KM7:TR?= NIraTJBUSU6JRWK=
KARPAS-45 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjSTWlKSzVyPUG1Mlc4OTZizszN NH7TcndUSU6JRWK=
SK-PN-DW NIKzR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nZVmlEPTB;MUWuPFY{OSEQvF2= NUX3[HE4W0GQR1XS
LC-2 NFOzV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fE[mlEPTB;MU[uNVUxPiEQvF2= NIfYcm1USU6JRWK=
NCI-H1648 NI\wV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF4LkK1OEDPxE1? NI\WO3NUSU6JRWK=
RL95-2 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vxZmlEPTB;MU[uN|k4QCEQvF2= MUHTRW5ITVJ?
KNS-42 M{XiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF4LkeyO|Qh|ryP NEe2eGVUSU6JRWK=
RPMI-6666 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLESXV[UUN3ME2xOk46OjFzIN88US=> NHSwSY5USU6JRWK=
SIG-M5 M4THPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDDdppKSzVyPUG3MlE6ODNizszN MX\TRW5ITVJ?
VA-ES-BJ NUXsdo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PHTGlEPTB;MUeuO|Q2OSEQvF2= NIPwbodUSU6JRWK=
MONO-MAC-6 NEDxfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTr[lc6UUN3ME2xO{46OzF{IN88US=> NVXPSlhOW0GQR1XS
LAN-6 M{DzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF6Lke1OVch|ryP M{XvbXNCVkeHUh?=
A388 NFPNT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7rZlJ2UUN3ME2xPU4{ODV7IN88US=> NVHKd|FUW0GQR1XS
SK-NEP-1 NHfWbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S1SGlEPTB;MkCuNlE{OiEQvF2= NGLBXFVUSU6JRWK=
TE-10 NG[2XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\PTWM2OD1{MD61NlIyKM7:TR?= NGnVdVdUSU6JRWK=
HL-60 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX5dXk1UUN3ME2yNE46ODl7IN88US=> MoHGV2FPT0WU
MC116 NELYeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJzLkeyNlEh|ryP M4DGWnNCVkeHUh?=
SW962 NIL4UldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fGXmlEPTB;MkGuO|kyPSEQvF2= M{TWc3NCVkeHUh?=
NOMO-1 NWTa[HVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfwOmRxUUN3ME2yNk43PTZ2IN88US=> NVztc|RMW0GQR1XS
CTB-1 NEO1fGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi5TINKSzVyPUKyMlg3PzFizszN NInl[lVUSU6JRWK=
MRK-nu-1 M1PYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ{LkmwO|Qh|ryP NGLUN5pUSU6JRWK=
GR-ST NYnhO4V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;PPHlKSzVyPUKzMlc3KM7:TR?= MlHLV2FPT0WU
HH MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3POWmlEPTB;MkSuNFA{KM7:TR?= NHXt[49USU6JRWK=
NCI-H1963 M2PkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTbIpKSzVyPUK0MlA4QDJizszN NE\FfHdUSU6JRWK=
QIMR-WIL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ2Lki3O|Ih|ryP MnPhV2FPT0WU
CGTH-W-1 M4\MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ3LkC3NlMh|ryP Mo\mV2FPT0WU
LP-1 NVfxd2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHhSXlKSzVyPUK1MlY2PTFizszN MnO5V2FPT0WU
NCI-H748 NIHQR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfvfmJVUUN3ME2yOk42OTN5IN88US=> NGnN[Y1USU6JRWK=
PF-382 NInaZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITiRopKSzVyPUK3MlIzOjNizszN M2LVd3NCVkeHUh?=
ATN-1 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTHfFJIUUN3ME2yO{4{PzN{IN88US=> NYroNIlLW0GQR1XS
L-540 M4DseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ5Lk[0OVkh|ryP NW\ZRVN[W0GQR1XS
LXF-289 NH;TWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7DTWM2OD1{Nz63OVE6KM7:TR?= NYXVbXNIW0GQR1XS
LS-513 NHXNPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvwS5llUUN3ME2yPE4yQDB5IN88US=> NGTJe2lUSU6JRWK=
NCI-H1581 NIH3eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37WTGlEPTB;M{CuN|k4PiEQvF2= MXXTRW5ITVJ?
ES6 NYDKcZRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNyLk[4PVkh|ryP Mn3YV2FPT0WU
SW982 NUP1SXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDre|dIUUN3ME2zNE45PTZ4IN88US=> MX;TRW5ITVJ?
DOHH-2 NHj6doNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\G[pFVUUN3ME2zNU42QDl|IN88US=> M3zWZXNCVkeHUh?=
DB M2PYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDLTWM2OD1|Mz65OFMyKM7:TR?= NVnEXmNiW0GQR1XS
MPP-89 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\LfGlEPTB;M{SuNVc2PiEQvF2= NWnB[4xTW0GQR1XS
LB831-BLC NWLDRoh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTN2LkWxPFQh|ryP MXnTRW5ITVJ?
NB5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Px[2lEPTB;M{SuPFU{PSEQvF2= MlzDV2FPT0WU
GB-1 NX\COWZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqzfppKSzVyPUO1MlA1PjlizszN MUDTRW5ITVJ?
TE-15 NInYVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;CfIVvUUN3ME2zOU4zOjN6IN88US=> M1\yOnNCVkeHUh?=
LC4-1 NFq5bY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMOXVKSzVyPUO1MlM5PDdizszN MnvWV2FPT0WU
NCI-H747 M{fOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXtUHVKSzVyPUO2MlE{PjlizszN NXu2elh{W0GQR1XS
NTERA-S-cl-D1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLTdZpKUUN3ME2zPE44OzR5IN88US=> M2qwSnNCVkeHUh?=
SK-MM-2 NULlXIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRyLkGxOFYh|ryP M1\BZnNCVkeHUh?=
TGW MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRzLkC1OlMh|ryP MnP1V2FPT0WU
ONS-76 NW\xWlRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X0R2lEPTB;NEKuOFg5OyEQvF2= MkHrV2FPT0WU
CPC-N M1LJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm2TWM2OD12Mj65PVcyKM7:TR?= MUPTRW5ITVJ?
ES4 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TSWmlEPTB;NESuOFE2OyEQvF2= MWHTRW5ITVJ?
Daudi MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvuWW56UUN3ME20OU4xQDJ5IN88US=> MoCwV2FPT0WU
MOLT-4 NISwSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HP[mlEPTB;NEWuNFg2OyEQvF2= MXjTRW5ITVJ?
HT-144 NVu2[JJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LHVWlEPTB;NE[uO|I3KM7:TR?= MUDTRW5ITVJ?
SW872 NULzeoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR6LkG5N|Mh|ryP MYTTRW5ITVJ?
D-283MED MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHqT2U{UUN3ME20PE4{PTR{IN88US=> M4faTXNCVkeHUh?=
NCI-H2126 NWqw[VlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr4dFJXUUN3ME20PE45PDd4IN88US=> NYfUdpNFW0GQR1XS
NCI-SNU-16 NXTZWnY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LK[GlEPTB;NEmuNlE1OyEQvF2= NWC2UolWW0GQR1XS
CESS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR7LkWwPFgh|ryP MWLTRW5ITVJ?
A101D MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\MZWlEPTB;NEmuPVc{PiEQvF2= M1\0[XNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
細胞試験:

[1]

+ 展開
  • 細胞株: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • 濃度: 0-256 nM
  • 反応時間: 1 hour
  • 実験の流れ:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • 製剤: --
  • 投薬量: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 450.34
化学式

C21H22Cl2FN5O

CAS No. 877399-52-5
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met信号経路図

c-Met Inhibitors with Unique Features

相関c-Met製品

Tags: Crizotinib (PF-02341066)を買う | Crizotinib (PF-02341066) ic50 | Crizotinib (PF-02341066)供給者 | Crizotinib (PF-02341066)を購入する | Crizotinib (PF-02341066)費用 | Crizotinib (PF-02341066)生産者 | オーダーCrizotinib (PF-02341066) | Crizotinib (PF-02341066)化学構造 | Crizotinib (PF-02341066)分子量 | Crizotinib (PF-02341066)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID